AKT1 and lung carcinoma: Furthermore, gefitinib-induced STAT3-Akt axis defined in this study also provides explanation for the mechanism of dramatic efficacy of combinational suppression of STAT3 or subsequent Akt/mTOR in overcoming acquired resistance in both in vitro and in vivo lung cancer models receiving EGFR TKI-based therapy [34-36].